Table 3. Best overall response of two groups.
| Variables | n (%) | P | |
| EP+A group (N=133) | EP group (N=92) | ||
| EP+A, atezolizumab plus EP chemotherapy; EP, EP chemotherapy; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease-control rate; DOR, duration of response. | |||
| Best overall response | 0.392 | ||
| CR | 3 (2.3) | 0 (0) | |
| PR | 83 (62.4) | 57 (62.0) | |
| SD | 25 (18.8) | 15 (16.3) | |
| PD | 2 (1.5) | 4 (4.3) | |
| ORR | 86 (64.7) | 57 (62.0) | 0.679 |
| DCR | 111 (83.5) | 72 (78.3) | 0.325 |
| DOR [median (95% CI)] (month) |
5.7 (3.4, 7.6) | 5.1 (3.4, 7.7) | 0.252 |
| Ongoing response | 38 (44.2) | 11 (19.3) | 0.002 |